Rialto Wealth Management LLC Invests $30,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 72 shares of the company’s stock, valued at approximately $30,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Insight Wealth Strategies LLC increased its holdings in shares of IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after purchasing an additional 7,041 shares during the period. Larson Financial Group LLC increased its stake in IDEXX Laboratories by 17,238.5% during the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after buying an additional 2,241 shares during the period. Quest Partners LLC increased its stake in IDEXX Laboratories by 4,059.4% during the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after buying an additional 2,801 shares during the period. Crystal Rock Capital Management lifted its stake in shares of IDEXX Laboratories by 90.0% in the 3rd quarter. Crystal Rock Capital Management now owns 9,005 shares of the company’s stock worth $4,550,000 after acquiring an additional 4,265 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of IDEXX Laboratories by 3.4% in the 3rd quarter. Victory Capital Management Inc. now owns 142,628 shares of the company’s stock worth $72,059,000 after acquiring an additional 4,696 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $430.12 on Monday. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $562.25. The firm has a 50-day moving average of $437.37 and a two-hundred day moving average of $449.09. The firm has a market capitalization of $34.98 billion, a PE ratio of 40.31, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Finally, Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $533.75.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.